Allogene Therapeutics, Inc. (ALLO)
Nasdaq: ALLO · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2018
Who owns Allogene Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Pfizer Inc. holds 9% of Common Stock, par value $0.001 per share (the "Common Stock"), as its SCHEDULE 13D/A filed Feb 13, 2026 says.
Directors and officers
14
report now, of 25 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Pfizer Inc.
SCHEDULE 13D/A · filed Feb 13, 2026 · Common Stock, par value $0.001 per share (the "Common Stock")
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.3% in Apr 17, 2025
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 4.7% in Apr 23, 2026
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
David D. Chang, M.D., Ph.D.
SCHEDULE 13G/A · filed May 13, 2026 · Common Stock · reported falling below 5%, from 5.2% in Feb 13, 2026
Fmr LLC
SCHEDULE 13G/A · filed Mar 7, 2025 · COMMON STOCK · reported falling below 5%, from 11.3% in Feb 12, 2025
Arie Belldegrun, M.D.
SCHEDULE 13G/A · filed Aug 7, 2026 · Common Stock · reported falling below 5%, from 5.4% in May 13, 2026
Kenneth Griffin
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share (the "Shares") · reported falling below 5%, from 6.1% in Jul 16, 2025
Tpg Gp A, LLC
SCHEDULE 13D/A · filed Sep 30, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%
Lynx1 Capital Management LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.2% in Feb 14, 2025
Capital World Investors
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock · reported falling below 5%, from 5.6% in May 13, 2025
What ALLO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Roche (Formerly Notch Therapeutics, Inc.)
An investee · investee · invested in, named in the 10-K filed Mar 12, 2026
Insider tradesForm 4
15sales
0purchases
0sales on a scheduled plan
6people selling
$700,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 23, 2025 to Oct 23, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 23, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Chang David D | President and CEO | 2 | $300,000 | 0 | 0 | $0 |
| Roberts Zachary | President and CEO | 2 | $100,000 | 0 | 0 | $0 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 2 | $100,000 | 0 | 0 | $0 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 5 | $100,000 | 0 | 0 | $0 |
| Douglas Earl Martin | SVP, General Counsel | 2 | $100,000 | 0 | 0 | $0 |
| Yoshiyama Annie | SVP, Finance | 2 | $0 | 0 | 0 | $0 |